How Entresto Patent Expiration Drives Price Drops
Entresto's main U.S. patents expire in 2025-2028, with key composition-of-matter protection ending January 2025 and method-of-use patents extending to 2028.[1] This triggers generic entry, slashing prices by 80-90% within 1-2 years, as seen with drugs like Eliquis (dropped 80% post-2023 generic launch).[2] Branded Entresto, now $600-700 monthly, could fall to $60-100 generics by late 2025.[3]
When Do Specific Patents Expire?
- Core patent (U.S. 8,877,938): January 26, 2025 – covers sacubitril/valsartan combo.[1]
- Pediatric exclusivity adds 6 months, pushing to July 2025.[1]
- Later patents (e.g., U.S. 10,471,104 for specific forms): Up to November 2028, but generics often launch at risk via Paragraph IV challenges.[1][4]
FDA approved first generic in March 2024 (LNX-01 by Lupin), but launch awaits patent settlements or court rulings.[5]
What Happens After Generic Entry?
Prices plummet due to competition: multiple generics flood the market, forcing deep discounts. PBMs and insurers shift patients quickly, pressuring Novartis revenue (Entresto generated $6B in 2023).[6] U.S. list prices may stay high initially for brand, but net prices crash via rebates.[3]
| Scenario | Timeline | Expected Price Impact |
|----------|----------|-----------------------|
| Smooth generic launch (post-Jan 2025) | 2025-2026 | 80-90% drop for generics vs. brand |
| Patent litigation delays | 2026-2028 | Slower entry, 50-70% initial drop |
| Authorized generic by Novartis | Immediate post-expiry | 40-60% drop, retains some share |
Will Biosimilars or Other Competitors Enter?
Entresto is a small-molecule drug, so generics (not biosimilars) compete directly. No major biosimilar pathway applies. Competitors like vericiguat (Verquvo) face their own patents until 2035, limiting substitution.[7]
Patient Access and Out-of-Pocket Costs
Medicare patients see fastest relief: generics enter formularies by Q4 2025, cutting copays from $50+ to $10 or less.[8] Uninsured face bigger drops but watch for initial generic shortages. Novartis may launch authorized generic at mid-tier pricing to capture volume.[3]
Novartis Strategies to Limit Price Erosion
Settlements with generics (e.g., Lupin deal allows 2025 entry) delay full competition.[5] Viatris and others challenge via ANDA filings.[1] Novartis pushes label expansions (e.g., HFpEF approval 2021) and coupons to retain share, but generics still dominate post-expiry.[6]
[1]: DrugPatentWatch.com - Entresto Patents
[2]: FDA Orange Book; IQVIA data
[3]: SSR Health pricing reports
[4]: USPTO Patent Term Calculator
[5]: Novartis Q1 2024 earnings; FDA ANDA approvals
[6]: Novartis annual report 2023
[7]: DrugPatentWatch.com - Verquvo
[8]: CMS Medicare Part D data